Amalgent
Chapel Hill, US · Founded 2020 · Delaware LLC · 2 employees on LinkedIn · 1 known investors
Amalgent is a clinical-stage pain management company developing oral combination drug therapeutics that repurpose existing medications to improve the safety of severe pain treatment. It initially targets the US market.
Founders & leadership
Amalgent was founded in 2020 by Malcolm A Meyn, Sam Tetlow, and Malcolm Meyn.
Investors · 1
Reported raises · per SEC filings
Form D private placements$200K disclosed across 1 round · 2022
▶$200KraisedApr 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$200KraisedApr 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Malcolm A MeynExecutive Officer, Director
- Sam TetlowDirector
- Offering amount
- $1M
- Amount sold
- $200K
- First sale
- Apr 2022
- Incorporated
- Limited Liability Company, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapEmergent Biosolutions6 shared keywordsEmergent BioSolutions is a public health company that develops, manufactures, and supplies medical countermeasures for national security and preparedness, along with commercialized products addressing threats such as the opioid epidemic. It also provides in-house development and manufacturing support to biopharma innovators, governments, and non-governmental organizations.
Schrodinger6 shared keywordsSchrödinger develops a physics-based computational platform for discovering and optimizing molecules, used to accelerate drug discovery and materials design. The company also operates a therapeutics group that pursues drug development on validated targets and offers educational resources for the field.
GentiBio5 shared keywordsGentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.
Teva4 shared keywordsTeva Pharmaceuticals is a biopharmaceutical company that develops innovative medicines across therapeutic areas such as neuroscience and immunology, alongside a large generics and biosimilars business. It serves patients and healthcare markets globally, focusing on both novel drugs and affordable generic and biologic medicines.
Companies competing with Amalgent for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Amalgent do?
- Amalgent is a clinical-stage pain management company developing oral combination drug therapeutics that repurpose existing medications to improve the safety of severe pain treatment. It initially targets the US market.
- Who founded Amalgent?
- Amalgent was founded by Malcolm A Meyn, Sam Tetlow, Malcolm Meyn in 2020.
- Who are Amalgent's investors?
- Amalgent's investors include The Innovation Space.
- How much funding has Amalgent raised?
- Amalgent has disclosed $200K raised across 1 round.
- Where is Amalgent headquartered?
- Amalgent is headquartered in Chapel Hill, US.